𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

✍ Scribed by C. Sillaber; H. Herrmann; K. Bennett; U. Rix; C. Baumgartner; A. Böhm; S. Herndlhofer; E. Tschachler; G. Superti-Furga; U. Jäger; P. Valent

Book ID
108713883
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
301 KB
Volume
39
Category
Article
ISSN
0014-2972

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib 140 mg once daily versus 70 mg
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
✍ Michael B. Lilly; Oliver G. Ottmann; Neil P. Shah; Richard A. Larson; Josy J. Re 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 1 views

## Abstract Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In patients with chronic‐phase chronic myelogenous leukemia, once‐daily dosing has similar efficacy with improved safety, compared wi